These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 6255572)

  • 21. Inhibition of dopamine receptors in the stomach: an explanation of the gastrokinetic properties of domperidone.
    Van Nueten JM; Ennis C; Helsen L; Laduron PM; Janssen PA
    Life Sci; 1978 Aug; 23(5):453-7. PubMed ID: 692268
    [No Abstract]   [Full Text] [Related]  

  • 22. The effect of intravenous domperidone on the resting lower oesophageal sphincter pressure in dogs and baboons.
    Kessler E; Bremner CH; Bremner CG
    S Afr Med J; 1979 Oct; 56(17):679-80. PubMed ID: 515866
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effects of dopamine D2 receptor antagonists on gastrointestinal motility].
    Mizumoto A; Ito A
    Nihon Heikatsukin Gakkai Zasshi; 1990 Apr; 26(2):65-9. PubMed ID: 2273688
    [No Abstract]   [Full Text] [Related]  

  • 24. [Comparative study of effects of gastrointestinal-motility control agents on rats and human colon].
    Sasaki D; Kawakami S; Yoshida Y
    Nihon Heikatsukin Gakkai Zasshi; 1990 Apr; 26(2):85-8. PubMed ID: 2273693
    [No Abstract]   [Full Text] [Related]  

  • 25. Measurement of gastric relaxation in the experimental animal: influence of domperidone.
    Lefebvre RA; Willems JL
    Arch Int Pharmacodyn Ther; 1978 Aug; 234(2):342-3. PubMed ID: 708159
    [No Abstract]   [Full Text] [Related]  

  • 26. Domperidone, a specific in vitro dopamine antagonist, devoid of in vivo central dopaminergic activity.
    Laduron PM; Leysen JE
    Biochem Pharmacol; 1979 Jul; 28(14):2161-5. PubMed ID: 496998
    [No Abstract]   [Full Text] [Related]  

  • 27. Reduction in vulnerability to ventricular fibrillation by bromocriptine, a dopamine agonist.
    Falk RH; Desilva RD; Lown B
    Cardiovasc Res; 1981 Mar; 15(3):175-80. PubMed ID: 7260985
    [TBL] [Abstract][Full Text] [Related]  

  • 28. L-646,462, a cyproheptadine-related antagonist of dopamine and serotonin with selectivity for peripheral systems.
    Williams M; Martin GE; Remy DC; Hichens M; Mangel AW; Taylor DA; Yarbrough GG; Bendesky RJ; King SW; Robinson JL
    J Pharmacol Exp Ther; 1984 Jun; 229(3):775-81. PubMed ID: 6547178
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Domperidone affects the interdigestive motility in the jejunum (author's transl)].
    Richter A; Erckenbrecht J; Wienbeck M
    Z Gastroenterol; 1981 Dec; 19(12):767-71. PubMed ID: 7034388
    [No Abstract]   [Full Text] [Related]  

  • 30. Dopamine-induced protection against indomethacin-evoked intestinal lesions in rats--role of anti-intestinal motility mediated by D2 receptors.
    Miyazawa T; Matsumoto M; Kato S; Takeuchi K
    Med Sci Monit; 2003 Feb; 9(2):BR71-7. PubMed ID: 12601282
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of domperidone on serum prolactin levels in human beings.
    Fujino T; Kato H; Yamashita S; Aramaki S; Morioka H; Koresawa M; Miyauchi F; Toyoshima H; Torigoe T
    Endocrinol Jpn; 1980 Aug; 27(4):521-5. PubMed ID: 7460861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cisapride and 5-hydroxytryptamine enhance motility in the canine antrum via separate pathways, not involving 5-hydroxytryptamine1,2,3,4 receptors.
    de Ridder WJ; Schuurkes JA
    J Pharmacol Exp Ther; 1993 Jan; 264(1):79-88. PubMed ID: 8093733
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of domperidone on pyloric activity in dog and in man.
    Platteborse R; Hermans C; Loots W; Van Loon J; Van Gorp A; Smet F; Jageneau A
    Postgrad Med J; 1979; 55 Suppl 1():15-8. PubMed ID: 471857
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preliminary observations on the interaction of domperidone with peripheral dopamine receptors.
    Willems JL; Bogaert MG; Buylaert W
    Jpn J Pharmacol; 1981 Feb; 31(1):131-3. PubMed ID: 7253336
    [No Abstract]   [Full Text] [Related]  

  • 35. [Pharmacology of an anticholinergic Sch-3444 or 4-(1-methyl-piperidyl)benzilate methylbromide. Experimental and clinical study].
    Maggi ND; Camponovo LE; Marchese MJ; Bertorello MC
    Prensa Med Argent; 1967 Apr; 54(8):375-9. PubMed ID: 5628940
    [No Abstract]   [Full Text] [Related]  

  • 36. [Oral use of domperidon for the treatment of chronic dyspepsia].
    Verhaegen H; Reyntjens A; Verbruggen F
    MMW Munch Med Wochenschr; 1978 Dec; 120(50):1689-90. PubMed ID: 102984
    [No Abstract]   [Full Text] [Related]  

  • 37. Effect of domperidone on prolactin secretion in healthy subjects.
    Uberti EC; Trasforini GC; Margutti AR; Sammaroli SR
    Panminerva Med; 1980 Jan-Mar 22; 22(1):13-5. PubMed ID: 7413230
    [No Abstract]   [Full Text] [Related]  

  • 38. In vitro and in vivo pharmacological characterization of PF-01354082, a novel partial agonist selective for the 5-HT(4) receptor.
    Mikami T; Komada T; Sugimoto H; Suzuki K; Ohmi T; Kimura N; Naganeo R; Nakata E; Nakatani K; Toga T; Eda H; Sakakibara M
    Eur J Pharmacol; 2009 May; 609(1-3):5-12. PubMed ID: 19285067
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The dopamine receptor antagonist domperidone is also a competitive antagonist at alpha 1-adrenoceptors.
    Ennis C; Cox B
    J Pharm Pharmacol; 1980 Jun; 32(6):434-5. PubMed ID: 6106681
    [No Abstract]   [Full Text] [Related]  

  • 40. [Pharmacologic and clinical differentiation of prokinetic drugs].
    May B; Greving I
    Leber Magen Darm; 1996 Jul; 26(4):193-8. PubMed ID: 8965601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.